As part of the Year in Review series, ALLMedPage Today reporters are revisiting major news stories and following up with an analysis of the impact of the original report, as well as subsequent news on the topic. Here's what's happened with the investigational multiple sclerosis drug laquinimod since we published the first 2011 piece on its safety and efficacy.Our Year in Review series highlights the major medical news stories of 2011. One of the bright spots in multiple sclerosis research this year was the emergence of laquinimod, an investigational oral drug, as a possible treatment for the disease. Here is the original article on the drug, published on April 14. In a companion article, you'll find out what has happened with it since.
Mayo Clinic is mourning the loss of Dr. Luis Bonilla, a cardiac surgeon, and David Hines, an organ procurement technician who, along with the pilot of the helicopter, perished during a mission to bring the gift of life to a … Continue reading →
Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported during the CRTC-AACR San Antonio Breast Cancer Symposium.
The results indicate activation of targets not previously associated with triple negative disease and could point ...
After reviewing published evidence, University of Missouri researchers conclude the benefits of exercise outweigh the risks for breast cancer survivors, including those who develop lymphedema, a chronic swelling that commonly occurs after breast cancer treatment. Co-author Jane Armer, professor in the University's Sinclair ...
This term describes several other types of fast heart rhythms that are not typically dangerous, but can cause symptoms of palpitations, fatigue, or shortness of breath. They typically start suddenly and stop suddenly, and may last for minutes or hours, with a rapid but steady pulse ...
Sonia was diagnosed with depression and was prescribed an antidepressant by her doctor. Over the next 5 years, Sonia took multiple antidepressants until a spiral into extreme mania led to her hospitalization and subsequent diagnosis of bipolar disorder. In retrospect, Sonia believes that if her ...The death of a multiple sclerosis patient shortly after a first dose of fingolimod (Gilenya) is under review by the FDA, the agency said.Certain clinical, imaging, and laboratory findings can help determine the etiology and prognosis in patients presenting with transverse myelitis, according to a new guideline from the American Academy of Neurology.The manufacturer of a major drug for multiple sclerosis has given what appears to be a money-back guarantee that its product will prevent severe relapses when used as directed.Demyelinating lesions in the brains of patients in the first stages of multiple sclerosis are not confined to the white matter, but also appear to be common in the gray-matter cortex, researchers said.